BLA number
103000
onabotulinumtoxinA
Botox, BLA 103000, is listed in the FDA Purple Book as a 351(a) biologic. This page consolidates 3 exact FDA presentation rows, and no exact reference-product relationship is asserted. It separates the BLA applicant from any unverified manufacturer and does not infer clinical labeling, pharmacy substitution, commercial availability, or patent conclusions.
Sourced from the FDA Purple Book · verified Oct 08, 2026
BLA number
103000
Regulatory role
351(a) biologic
Applicant
AbbVie Inc.
Applicant is not automatically the physical manufacturer.
Presentations
3
Exact FDA presentation rows under this BLA.
Approval
Dec 09, 1991
Reference product
Not stated
Botox is an FDA-licensed 351(a) biologic.
No 351(k) product in the loaded Purple Book family data explicitly references Botox.
Substitution boundary
The absence of a linked 351(k) record is a bounded database result, not proof that the product can never serve as a reference product.
Approval
Approval date of this BLA submission.
Dec 09, 1991
35 yr 6 mo ago
Orphan exclusivity ends
7-year orphan-drug exclusivity window.
Jun 20, 2026
5 mo ago
Today
Strength
50UNITS
Dosage form
For Injection
Route
Injection, Intramuscular, Intradermal, Intradetrusor
Presentation
Single-Dose Vial
Center
CDER
License number
1889
Product number
003
Submission type
Original
Supplement number
Not listed
Change type
Not listed
Strength
100UNITS
Dosage form
For Injection
Route
Injection, Intramuscular, Intradermal, Intradetrusor
Presentation
Single-Dose Vial
Center
CDER
License number
1889
Product number
004
Submission type
Original
Supplement number
Not listed
Change type
Not listed
Strength
200UNITS
Dosage form
For Injection
Route
Injection, Intramuscular, Intradermal, Intradetrusor
Presentation
Single-Dose Vial
Center
CDER
License number
1889
Product number
005
Submission type
Original
Supplement number
Not listed
Change type
Not listed
One row per FDA presentation under this exact BLA. Missing cells remain unavailable rather than being borrowed from another product.
| Product | Strength | Dosage form | Route | Presentation | Licensure | Marketing |
|---|---|---|---|---|---|---|
| 003 | 50UNITS | For Injection | Injection, Intramuscular, Intradermal, Intradetrusor | Single-Dose Vial | Licensed | Disc |
| 004 | 100UNITS | For Injection | Injection, Intramuscular, Intradermal, Intradetrusor | Single-Dose Vial | Licensed | Rx |
| 005 | 200UNITS | For Injection | Injection, Intramuscular, Intradermal, Intradetrusor | Single-Dose Vial | Licensed | Rx |
The rows above are this brand's presentations. FDA also lists the brand below on this BLA, each with its own presentation rows. Strength and reference product come from each brand's own rows; a shared BLA does not establish shared presentations, approved uses, or substitutability.
Current product label
Candidate awaiting exact-BLA match
FDA exposes a label link on this Purple Book row, but labeling content remains unavailable until the document is independently matched to this exact BLA and its presentations.
Inspect FDA label candidateFDA approval evidence
Not applicable to 351(a)
A biosimilar totality-of-evidence summary is not applicable to this 351(a) record. Product-specific clinical content still requires an exact-BLA label or review source.
Human review pending
Automated BLA-level interpretation has not been marked human-reviewed. The research queue contains 1 exact-source task. Labeling and approval-review claims stay unavailable until their own match gate passes.
The current record does not expose a reference-product name or an exact linked 351(k) family for Botox.
No reference product is stated in this exact Purple Book row. This is a bounded snapshot result, not proof of real-world absence.
No patent-list records were published for this product. The Purple Book patent list reflects the statutory patent exchange under the BPCIA and is not exhaustive.
3 exact FDA presentation rows are consolidated under this BLA rather than split across duplicate pages.
The loaded rows list Injection, Intramuscular, Intradermal, Intradetrusor and For Injection; these are regulatory presentation fields, not dosing instructions.
AbbVie Inc. is the listed BLA applicant. The page does not relabel the applicant as manufacturer, labeler, distributor, or commercial supplier without an exact product-specific source.
Botox is an FDA-licensed 351(a) biologic. Family comparisons preserve each BLA's own designation and do not use Orange Book therapeutic-equivalence terminology.
Licensure, biosimilar status, exclusivity, and patents for this biologic, from the FDA Purple Book.
Built directly from the FDA Purple Book database of licensed biological products. License types, approval and exclusivity dates, and the patent list match the official FDA record. The Purple Book patent list reflects the statutory BPCIA patent exchange and is not exhaustive.
Assyro Intelligence
Cited answers from FDA, EMA, Health Canada, PubMed and ClinicalTrials.gov, in seconds. Free, no sign-up.
Evaluating for a team? Book a demo